RootLoc Co., Ltd.
KKRX:253610500.00
KRW
0.00
(0.00%)
ISIN
KR7253610000
Return %
Stock
S&P 500
1Y
-57.98
14.39
3Y
-66.22
81.42
5Y
-81.62
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Jong-Jin Park
- Full Time Employees
- 27
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seoul South Korea
- IPO Date
- Dec 24, 2020
- Website
- rootloc.com
- Similar Companies
- Business
- RootLoc Co., Ltd. is a South Korea-based medical device company that develops, manufactures, and commercializes orthopedic implants and surgical solutions. The company operates in the orthopedic and musculoskeletal healthcare sector, providing joint reconstruction and spinal stabilization systems to hospitals, specialized clinics, and orthopedic surgical centers across domestic and international markets. Its product portfolio comprises artificial joint prostheses, including the flagship CentLoc total knee replacement system and artificial hip joint implants; spinal fixation systems, including the CentLoc-LP spinal fixation system featuring poly-axial, mono-axial, cannulated, and reduction pedicle screws, spinal rods, and transverse connectors; interspinous stabilization devices; antibacterial bone cements; medical washers; and proprietary orthopedic surgical instrumentation. RootLoc maintains integrated batch manufacturing facilities in Cheonan-si, Chungcheongnam-do, and is headquartered in Geumcheon-gu, Seoul, South Korea. Founded in 2014 and operating as an affiliate of L&K Biomed Co., Ltd., the company is publicly traded on the Korea New Exchange under ticker KRX:253610. In recent strategic developments, RootLoc expanded its global market footprint by partnering with US-based medical distributor Aegis Spine, Inc. to commercialize and export its U.S. FDA-cleared CentLoc knee implant system across healthcare networks in the United States. Furthermore, the company secured a five-year supply agreement valued at approximately KRW 12.6 billion to supply CentLoc joint implants to Indonesia and adjusted its convertible bond conversion terms to optimize capital allocation for ongoing international regulatory approvals and commercial scale-up.